bluebird bio
NEWS
bluebird bio is hitting back at Spark Therapeutics over the use of the word “spark” involving the company’s “Be the Spark” campaign against sickle cell disease.
The 2021 EHA is in full swing. BioSpace is rounding up several presentations from the past two days. Here are some of them.
The FDA lifted the clinical holds on bluebird bio’s sickle gene therapy and its betibeglogene autotemcel gene therapy for adults, adolescents and children with TDT.
BioSpace looks at five of the top investor companies that support life sciences companies across the industry.
Gene therapy is still very much cutting-edge with the potential to cure incurable genetic diseases. Here’s some recent news in the space.
Bluebird bio reported first-quarter earnings, the approval of Abecma, the first CAR-T therapy for relapsed or refractory multiple myeloma, and its spinout, 2seventy bio, and its leadership.
Davidson is one of three new executives to join Cambridge, Mass.-based Tessera.
The FDA-approved ide-cel, which will be marketed under the brand name Abecma is going to be the second therapy for myeloma. Here’s everything you need to know.
It was a relatively quiet week in terms of clinical trial news, but there were some significant releases. Here’s a look.
JOBS